 Mario Enrico Canonico
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 5 | 2024 | 457 | 2.340 |
Why?
| | Acute Coronary Syndrome | 8 | 2025 | 267 | 2.270 |
Why?
| | Percutaneous Coronary Intervention | 10 | 2025 | 467 | 1.700 |
Why?
| | Platelet Aggregation Inhibitors | 13 | 2025 | 442 | 1.350 |
Why?
| | Lower Extremity | 4 | 2024 | 404 | 1.200 |
Why?
| | Aspirin | 5 | 2024 | 380 | 1.160 |
Why?
| | Rivaroxaban | 3 | 2024 | 252 | 1.160 |
Why?
| | Fibrinolytic Agents | 4 | 2024 | 262 | 1.010 |
Why?
| | Factor Xa Inhibitors | 2 | 2024 | 170 | 1.010 |
Why?
| | ST Elevation Myocardial Infarction | 2 | 2022 | 52 | 0.870 |
Why?
| | Thrombosis | 2 | 2024 | 343 | 0.770 |
Why?
| | Anticholesteremic Agents | 1 | 2023 | 150 | 0.730 |
Why?
| | Venous Thrombosis | 1 | 2022 | 175 | 0.660 |
Why?
| | Coronavirus | 1 | 2020 | 43 | 0.650 |
Why?
| | Mobile Applications | 1 | 2022 | 160 | 0.650 |
Why?
| | Blood Platelets | 3 | 2024 | 380 | 0.650 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 430 | 0.610 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 339 | 0.610 |
Why?
| | Coronavirus Infections | 2 | 2020 | 333 | 0.600 |
Why?
| | Purinergic P2Y Receptor Antagonists | 6 | 2025 | 66 | 0.590 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 284 | 0.570 |
Why?
| | Sex Characteristics | 1 | 2023 | 736 | 0.570 |
Why?
| | Heart Failure | 4 | 2024 | 2135 | 0.560 |
Why?
| | Precision Medicine | 1 | 2021 | 386 | 0.550 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 566 | 0.530 |
Why?
| | Neoplasms | 4 | 2024 | 2449 | 0.490 |
Why?
| | Adenosine Monophosphate | 3 | 2025 | 63 | 0.450 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1000 | 0.440 |
Why?
| | Platelet Aggregation | 3 | 2024 | 95 | 0.440 |
Why?
| | Stroke Volume | 5 | 2024 | 592 | 0.420 |
Why?
| | Hypertension | 4 | 2025 | 1242 | 0.420 |
Why?
| | Postoperative Complications | 1 | 2024 | 2473 | 0.410 |
Why?
| | Pandemics | 2 | 2020 | 1482 | 0.400 |
Why?
| | Ventricular Function, Left | 4 | 2024 | 527 | 0.380 |
Why?
| | Coronary Artery Disease | 3 | 2024 | 679 | 0.380 |
Why?
| | Humans | 38 | 2025 | 129248 | 0.370 |
Why?
| | Antihypertensive Agents | 2 | 2025 | 485 | 0.350 |
Why?
| | Anticoagulants | 4 | 2022 | 636 | 0.320 |
Why?
| | Drug Therapy, Combination | 4 | 2024 | 1040 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2439 | 0.290 |
Why?
| | Betacoronavirus | 2 | 2020 | 248 | 0.280 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 385 | 0.280 |
Why?
| | Atrial Fibrillation | 2 | 2021 | 376 | 0.270 |
Why?
| | Coronary Angiography | 4 | 2021 | 305 | 0.230 |
Why?
| | Treatment Outcome | 10 | 2025 | 10199 | 0.230 |
Why?
| | Morphine Derivatives | 1 | 2023 | 17 | 0.220 |
Why?
| | Tablets | 1 | 2023 | 35 | 0.220 |
Why?
| | International Classification of Diseases | 1 | 2024 | 122 | 0.220 |
Why?
| | Subtilisin | 1 | 2023 | 3 | 0.210 |
Why?
| | Proprotein Convertases | 1 | 2023 | 15 | 0.210 |
Why?
| | Male | 18 | 2025 | 63501 | 0.210 |
Why?
| | Aged | 12 | 2025 | 22032 | 0.210 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 68 | 0.200 |
Why?
| | Middle Aged | 12 | 2025 | 31087 | 0.200 |
Why?
| | Hemorrhage | 2 | 2024 | 678 | 0.200 |
Why?
| | Atrial Remodeling | 1 | 2022 | 9 | 0.190 |
Why?
| | Adenosine | 1 | 2023 | 227 | 0.190 |
Why?
| | Echocardiography | 5 | 2024 | 629 | 0.190 |
Why?
| | Bundle-Branch Block | 1 | 2021 | 30 | 0.190 |
Why?
| | Frailty | 1 | 2024 | 153 | 0.180 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 30 | 0.180 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 294 | 0.180 |
Why?
| | Cardiotoxicity | 1 | 2021 | 33 | 0.180 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 358 | 0.180 |
Why?
| | Drug Compounding | 1 | 2021 | 97 | 0.180 |
Why?
| | Atherosclerosis | 1 | 2025 | 402 | 0.180 |
Why?
| | Coronary Stenosis | 1 | 2020 | 39 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 232 | 0.170 |
Why?
| | Coronary Occlusion | 1 | 2020 | 18 | 0.170 |
Why?
| | Aged, 80 and over | 4 | 2024 | 7055 | 0.170 |
Why?
| | Cardiology | 1 | 2023 | 261 | 0.170 |
Why?
| | Female | 14 | 2025 | 68543 | 0.170 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 72 | 0.170 |
Why?
| | Prevalence | 3 | 2021 | 2554 | 0.170 |
Why?
| | Radial Artery | 2 | 2021 | 69 | 0.170 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2021 | 140 | 0.170 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 60 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2024 | 405 | 0.170 |
Why?
| | Myocarditis | 1 | 2021 | 98 | 0.170 |
Why?
| | Angioplasty, Balloon | 1 | 2021 | 91 | 0.160 |
Why?
| | Double-Blind Method | 1 | 2024 | 1875 | 0.160 |
Why?
| | Heart Arrest | 1 | 2023 | 320 | 0.160 |
Why?
| | Students, Medical | 1 | 2023 | 315 | 0.150 |
Why?
| | Hepatitis C, Chronic | 1 | 2020 | 153 | 0.150 |
Why?
| | Pulmonary Embolism | 1 | 2020 | 211 | 0.150 |
Why?
| | Cardiomyopathies | 1 | 2021 | 340 | 0.140 |
Why?
| | Blood Pressure | 2 | 2024 | 1736 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 1367 | 0.130 |
Why?
| | Hypoglycemic Agents | 1 | 2024 | 1219 | 0.120 |
Why?
| | Hospitalization | 1 | 2024 | 2052 | 0.120 |
Why?
| | Femoral Artery | 1 | 2016 | 173 | 0.120 |
Why?
| | Risk Factors | 3 | 2025 | 9745 | 0.120 |
Why?
| | Registries | 4 | 2025 | 1895 | 0.120 |
Why?
| | Heart Ventricles | 1 | 2020 | 781 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 518 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2053 | 0.100 |
Why?
| | Italy | 2 | 2023 | 100 | 0.100 |
Why?
| | Disease Management | 2 | 2025 | 588 | 0.090 |
Why?
| | United States | 2 | 2024 | 13828 | 0.080 |
Why?
| | Administration, Oral | 2 | 2021 | 785 | 0.080 |
Why?
| | Prognosis | 3 | 2021 | 3772 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2003 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2024 | 14455 | 0.070 |
Why?
| | Adult | 3 | 2022 | 35495 | 0.060 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2024 | 6 | 0.060 |
Why?
| | Platelet Function Tests | 1 | 2024 | 25 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2024 | 768 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2024 | 521 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5045 | 0.050 |
Why?
| | Emergencies | 1 | 2023 | 155 | 0.050 |
Why?
| | Prasugrel Hydrochloride | 1 | 2022 | 22 | 0.050 |
Why?
| | Prospective Studies | 2 | 2025 | 7121 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 99 | 0.050 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2021 | 56 | 0.050 |
Why?
| | Gadolinium | 1 | 2021 | 78 | 0.050 |
Why?
| | Vitamin K | 1 | 2021 | 41 | 0.050 |
Why?
| | Heart Atria | 1 | 2022 | 128 | 0.050 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2020 | 126 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 239 | 0.040 |
Why?
| | Hepacivirus | 1 | 2020 | 235 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 393 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 978 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2022 | 692 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 231 | 0.040 |
Why?
| | Age Factors | 1 | 2024 | 3140 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2008 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1946 | 0.030 |
Why?
| | Stents | 1 | 2020 | 502 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1984 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1544 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6543 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2636 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2737 | 0.030 |
Why?
| | Body Mass Index | 1 | 2022 | 2272 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 569 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 285 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 3233 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5408 | 0.020 |
Why?
| | Length of Stay | 1 | 2016 | 1120 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 3966 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1364 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1894 | 0.020 |
Why?
| | Animals | 1 | 2021 | 35307 | 0.010 |
Why?
|
|
Canonico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|